These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37676480)

  • 1. Using race as a social construct when looking at differences in racial associations between non-alcoholic fatty liver disease and type 2 diabetes.
    Rollin FG; Washington C; Fluker SA
    Diabetologia; 2024 Jan; 67(1):211-212. PubMed ID: 37676480
    [No Abstract]   [Full Text] [Related]  

  • 2. Using race as a social construct when looking at differences in racial associations between non‑alcoholic fatty liver disease and type 2 diabetes. Reply to Rollin FG, Washington C, Fluker S-A [letter].
    Hatano Y; VanWagner LB; Carnethon MR; Bancks MP; Carson AP; Lloyd-Jones DM; Østbye T; Viera AJ; Yano Y
    Diabetologia; 2024 Jan; 67(1):213-214. PubMed ID: 37882861
    [No Abstract]   [Full Text] [Related]  

  • 3. Does race or ethnicity play a role in the origin, pathophysiology, and outcomes of preeclampsia? An expert review of the literature.
    Johnson JD; Louis JM
    Am J Obstet Gynecol; 2022 Feb; 226(2S):S876-S885. PubMed ID: 32717255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial Health Equity and Social Needs Interventions: A Review of a Scoping Review.
    Cené CW; Viswanathan M; Fichtenberg CM; Sathe NA; Kennedy SM; Gottlieb LM; Cartier Y; Peek ME
    JAMA Netw Open; 2023 Jan; 6(1):e2250654. PubMed ID: 36656582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial difference in the association between non-alcoholic fatty liver disease and incident type 2 diabetes: findings from the CARDIA study.
    Hatano Y; VanWagner LB; Carnethon MR; Bancks MP; Carson AP; Lloyd-Jones DM; Østbye T; Viera AJ; Yano Y
    Diabetologia; 2023 Jul; 66(7):1235-1246. PubMed ID: 36941389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Practices in Operationalizing and Addressing Racial Equity in the Provision of Type 1 Diabetes Care: Insights from the Type 1 Diabetes Exchange Quality Improvement Collaborative Health Equity Advancement Lab.
    Addala A; Mungmode A; Ospelt E; Sanchez JE; Malik F; Demeterco-Berggren C; Butler A; Edwards C; Manukyan M; Ochoa-Maya M; Zupa M; Ebekozien O
    Endocr Pract; 2024 Jan; 30(1):41-48. PubMed ID: 37806550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Per- and Polyfluoroalkyl Substances and Obesity, Type 2 Diabetes and Non-alcoholic Fatty Liver Disease: A Review of Epidemiologic Findings.
    Qi W; Clark JM; Timme-Laragy AR; Park Y
    Toxicol Environ Chem; 2020; 102(1-4):1-36. PubMed ID: 33304027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The white racial frame of public health discourses about racialized health differences and "disparities": what it reveals about power and how it thwarts health equity.
    Bowleg L
    Front Public Health; 2023; 11():1187307. PubMed ID: 37822536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-Like Peptide-1 Receptor Agonists for Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: A Meta-Analysis.
    Wong C; Lee MH; Yaow CYL; Chin YH; Goh XL; Ng CH; Lim AYL; Muthiah MD; Khoo CM
    Front Endocrinol (Lausanne); 2021; 12():609110. PubMed ID: 33897616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Culture, Race, and Health: Implications for Racial Inequities and Population Health.
    Cogburn CD
    Milbank Q; 2019 Sep; 97(3):736-761. PubMed ID: 31512293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twenty-five-year trajectories of insulin resistance and pancreatic β-cell response and diabetes risk in nonalcoholic fatty liver disease.
    VanWagner LB; Ning H; Allen NB; Siddique J; Carson AP; Bancks MP; Lewis CE; Carr JJ; Speliotes E; Terrault NA; Rinella ME; Vos MB; Lloyd-Jones DM
    Liver Int; 2018 Nov; 38(11):2069-2081. PubMed ID: 29608255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review of how social connectedness influences associations between racism and discrimination on health outcomes.
    Ransome Y; Valido AD; Espelage DL; Clements GL; Harrell C; Eckel C; Price N; Nassau R; Nyhan K; Taggart TL
    Epidemiol Rev; 2023 Dec; 45(1):44-62. PubMed ID: 37477041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cigarette Smoking Increases the Risk of Type 2 Diabetes Mellitus in Patients with Non-Alcoholic Fatty Liver Disease: A Population-Based Cohort Study.
    Liu C; Wu Y; Duan W; Xu W
    Exp Clin Endocrinol Diabetes; 2022 Dec; 130(12):793-800. PubMed ID: 35359014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated serum cytokeratin-18 concentration in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease.
    Chang YH; Lin HC; Hwu DW; Chang DM; Lin KC; Lee YJ
    Ann Clin Biochem; 2019 Jan; 56(1):141-147. PubMed ID: 30089409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
    Yi M; Chen RP; Yang R; Chen H
    Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategic Messaging to Promote Policies that Advance Racial Equity: What Do We Know, and What Do We Need to Learn?
    Niederdeppe J; Liu J; Spruill M; Lewis NA; Moore S; Fowler EF; Gollust SE
    Milbank Q; 2023 Jun; 101(2):349-425. PubMed ID: 37096590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes.
    Jenks SJ; Conway BR; Hor TJ; Williamson RM; McLachlan S; Robertson C; Morling JR; Strachan MW; Price JF
    Diabet Med; 2014 Sep; 31(9):1039-46. PubMed ID: 24684407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management.
    Byrne CD
    Diabet Med; 2012 Sep; 29(9):1098-107. PubMed ID: 22672330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.